Please login to the form below

Not currently logged in
Email:
Password:

linagliptin

This page shows the latest linagliptin news and features for those working in and with pharma, biotech and healthcare.

Boehringer Ingelheim calls for "strong and united" Europe

Boehringer Ingelheim calls for

In particular, Eli Lilly-partnered diabetes franchise based on DPP-4 inhibitor Trajenta (linagliptin) climbed 23% to 1.1bn while sales of lung disease therapy Ofev (nintedanib) more than doubled to

Latest news

More from news
Approximately 3 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Notable points are that despite the considerable promotion and, some would say, superior clinical data, none of the SGLT2s has exceeded Trajenta (linagliptin) - a 4th entrant DPP4 in sales.

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    This includes Germany-based Boehringer Ingelheim's disapproval of the generic comparator used in IQWiG's AMNOG assessment of the diabetes medicine Trajenta (linagliptin).

  • A new dogma in HTA assessment A new dogma in HTA assessment

    The G-BA had specified that linagliptin should be compared with a drug from the sulphonylurea class, such as glibenclamide or glimepiride. ... However, IQWiG was unable to infer any such benefit from the dossier because the manufacturers compared

  • Country report: The healthcare market in Germany Country report: The healthcare market in Germany

    Out of the 10 products assessed last year, four have obtained poor innovation scores: Esbriet (pirfenidone), Livazo (pitavastatin), Yellox (bromfenac) and Trajenta (linagliptin) and a majority of manufacturers have struggled – sometimes

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics